Meloxicam Lador Empifarma - Produtos Farmacêuticos

Meloxicam, the active ingredient in Meloxicam Lador Empifarma, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It is indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute pain in adult patients, helping to reduce inflammation and improve functional ability and quality of life.

GNH USA supplies Meloxicam Lador Empifarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution.

Meloxicam is an NSAID that reduces inflammation by selectively inhibiting COX‑2, and it is used in several musculoskeletal conditions.

Osteoarthritis: alleviates joint pain and stiffness, improving mobility. Rheumatoid arthritis: decreases synovial inflammation and pain, aiding disease management. Ankylosing spondylitis: reduces spinal inflammation and pain, enhancing function. Acute pain: provides rapid analgesic effect for short‑term pain relief.

Meloxicam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort (nausea, dyspepsia) - Headache - Dizziness

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Severe cardiovascular events (myocardial infarction, stroke) - Hepatic enzyme elevation or hepatitis

When prescribing meloxicam, clinicians should consider several safety measures.

Assess gastrointestinal risk: evaluate history of ulcers before initiating therapy. Monitor cardiovascular status: use the lowest effective dose in patients with heart disease. Use caution in renal impairment: adjust therapy if renal function is reduced. Avoid in known hypersensitivity to meloxicam or other NSAIDs. Store at below 25°C: keep in the original pack, protect from moisture.

Meloxicam can interact with a variety of medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Lithium: increased serum lithium levels. - Methotrexate: reduced clearance, potential toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function. - Diuretics: risk of renal impairment. - SSRIs or SNRIs: heightened bleeding tendency.